| Add to balance / Manage account | User: | Log out |
| Prospect News home > News index > List of issuers A > Headlines for Array BioPharma Inc. > News item |
Array BioPharma begins phase 1 trial of MEK inhibitor for inflammatory disease
By E. Janene Geiss
Philadelphia, April 26 - Array BioPharma Inc. announced Wednesday the start of a phase 1 clinical trial in the United States for its proprietary small molecule, ARRY-438162, a novel MEK inhibitor for the treatment of inflammatory disease.
ARRY-438162 will be evaluated in dose escalation studies in healthy volunteers, according to a company news release. Array scientists demonstrated ARRY-438162 to be potent, selective, well-tolerated and efficacious in preclinical models of human inflammatory diseases, officials said.
MEK is a protein kinase that regulates both the biosynthesis of and response to a number of growth factors that drive uncontrolled inflammation associated with many human diseases.
Array said its scientists have discovered multiple series of MEK inhibitors that selectively interfere with these critical disease processes.
Its first MEK inhibitor, ARRY-142886, was licensed to AstraZeneca AB for cancer and is in clinical development.
Array's new proprietary molecule, ARRY-438162, is well-tolerated and efficacious in various preclinical models of human diseases driven by inflammatory growth factors like TNFalpha, IL-1 and IL-6, officials said.
These results lead Array scientists to believe that MEK inhibition will be useful in treating acute and chronic inflammatory diseases, including rheumatoid arthritis, chronic obstructive pulmonary disease and inflammatory bowel disease, officials said.
Array is a Boulder, Colo., biopharmaceutical company focused on the development and commercialization of orally active drugs to address significant unmet medical needs.
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.